Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Vipoma 1Somatostatinoma 1Recurrence 1Pleural Effusion 1Paraganglioma 1Neuroendocrine Tumors 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Chylous Ascites 1Chylothorax 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Ascites 1

Interventions

gallium Ga 68 dotatate 3Specimen Handling 3Temozolomide 2Magnetic Resonance Spectroscopy 2talazoparib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1guadecitabine 1cixutumumab 1Salts 1Octreotide 1Nivolumab 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Contrast Media 1CTLA-4 Antigen 1Biopsy 1Axitinib 1Acetates 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Paraganglioma × Octreotide × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡